Management of Post-Liver Transplant Recurrence of Hepatitis C
- 23 November 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 76 (18), 1711-1717
- https://doi.org/10.1007/s40265-016-0658-0
Abstract
Cirrhosis due to chronic hepatitis C (HCV) is the leading indication for liver transplantation in North America and Europe. HCV re-infection post-transplant is nearly universal and if left untreated negatively affects patient and graft survival. Until recently, treatment options for HCV were limited to interferon (IFN)-based therapies which had low sustained viral response (SVR) rates and were poorly tolerated in the post-transplant setting. In the last 3 years, the promise of the directly acting antivirals (DAAs) for the treatment of HCV has been fulfilled with high sustained viral response (SVR) rates and a low side effect profile demonstrated in both registration trials and real-world studies. This innovation has allowed post-liver transplant patients with HCV recurrence access to interferon-free therapies with extraordinary efficacy, safety, tolerability, and fewer drug-drug interactions.Keywords
This publication has 44 references indexed in Scilit:
- High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated CirrhosisGastroenterology, 2016
- Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 InfectionsGastroenterology, 2016
- Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 InfectionAnnals of Internal Medicine, 2015
- Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical TrialsClinical Infectious Diseases, 2014
- Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with RibavirinThe New England Journal of Medicine, 2014
- Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890Journal of Hepatology, 2013
- Post-liver transplant cholestatic hepatitis C: A systematic review of clinical and pathological findings and application of consensus criteriaLiver Transplantation, 2010
- Fibrosing cholestatic hepatitis with hepatitis C virus treated by double filtration plasmapheresis and interferon plus ribavirin after liver transplantationClinical Journal of Gastroenterology, 2009
- Interferon-Based Combination Anti-Viral Therapy for Hepatitis C Virus After Liver Transplantation: A Review and Quantitative AnalysisAmerican Journal of Transplantation, 2006
- The association between hepatitis C infection and survival after orthotopic liver transplantationGastroenterology, 2002